Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.
about
A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma.Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature.Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.m-TOR inhibitors and their potential role in haematological malignancies.Long-term safety and activity of cladribine in patients with extranodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.Nodular pulmonary amyloidosis with primary pulmonary MALT lymphoma masquerading as metastatic lung disease.High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial.A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial.A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study.Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma.Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients.
P2860
Q33443555-917E6E64-67BB-4E34-A902-904E02C6199FQ38544142-55E16F34-973B-4341-991C-46D76366CDA0Q38819164-D13D3515-F8E1-447D-AE4A-1B1F16288819Q38947867-5E72D12E-7460-4729-9A99-C863F8A98305Q39113506-9C892DA8-0967-460D-A49D-0ACA856E3077Q40308641-4901799A-37F7-4910-92AE-AF1A376F72A1Q41197838-D7E2DB0B-AB14-41EE-9FAD-8F3D1186A4F9Q41263804-5E2D1E4F-36D0-42FC-830D-C99957A139DBQ41298970-CE4475C1-EAE0-4A4D-829F-495487D0B1A2Q41665957-F5461751-4129-4BAE-B723-AA815EC4FF02Q47119181-B1F99716-C9D9-46CA-AD76-9E0A0F62B701Q47320024-9645EC93-BE0D-4724-A148-64E0BFCF11BE
P2860
Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Clinical activity of everolimu ...... tranodal Lymphoma Study Group.
@ast
Clinical activity of everolimu ...... tranodal Lymphoma Study Group.
@en
type
label
Clinical activity of everolimu ...... tranodal Lymphoma Study Group.
@ast
Clinical activity of everolimu ...... tranodal Lymphoma Study Group.
@en
prefLabel
Clinical activity of everolimu ...... tranodal Lymphoma Study Group.
@ast
Clinical activity of everolimu ...... tranodal Lymphoma Study Group.
@en
P2093
P2860
P50
P356
P1476
Clinical activity of everolimu ...... tranodal Lymphoma Study Group.
@en
P2093
Anastasios Stathis
Andrés J M Ferreri
Annarita Conconi
Elena Porro
Franco Cavalli
Markus Raderer
Massimo Magagnoli
Silvia Franceschetti
P2860
P356
10.1111/BJH.12845
P407
P50
P577
2014-03-27T00:00:00Z